What APONTIS PHARMA does

APONTIS PHARMA Deutschland GmbH & Co. KG is a Germany-focused specialty pharmaceutical company headquartered in Monheim am Rhein, operating as 'The Single Pill Company'. It develops, in-licenses, and markets fixed-dose combination products ('Single Pills') that merge two to three off-patent active ingredients into a single tablet, primarily for cardiovascular indications including hypertension, dyslipidemia, and cardiovascular secondary prophylaxis. The portfolio currently includes 11 launched Single Pill brands (e.g., Tonotec, Caramlo, AmloAtor APONTIS, Iltria, RosuAmlo APONTIS) with a stated goal of at least 20 by 2026, alongside co-promoted respiratory products (Atectura Breezhaler, Enerzair Breezhaler) and legacy brands such as Colxi, magno sanol, and Obstinol M. The company was founded in 1946 as Schwarz Pharma, became part of UCB's Internal Medicine segment, was carved out in 2016, acquired by Paragon Partners in 2018, renamed APONTIS PHARMA in 2019, and completed an IPO in May 2021; it now operates as part of the Zentiva Group (Prague-headquartered) under joint GDPR controllership.

The company makes money primarily through wholesale pharmaceutical product sales in Germany, distributed through the regulated German pharma supply chain (wholesalers → pharmacies → patients, plus direct clinic supply under §14 Apothekengesetz). A secondary revenue stream comes from co-promotion and fee-for-call arrangements where APONTIS PHARMA deploys its field sales force to promote partner products to its established physician base. Go-to-market is anchored by a dedicated field sales force (Pharmaberater) maintaining direct in-person relationships with approximately 23,500 office-based physicians across Germany, supplemented by digital engagement tools ('Erfolgs-Rezept direkt', 'Erfolgs-Rezept online'), medical congress presence, and an English/German corporate website. Customer segments include primary-care physicians (primary), specialists, retail and hospital pharmacies, and pharmaceutical company partners seeking primary-care market access. Pricing follows standard ex-works Germany unit pricing with tiered minimum-order rules, free-house delivery above €150, a 5% small-order surcharge below €500, and 30-day net payment terms with 1% SEPA discount within 10 days. Distribution is contractually restricted to Germany — international sales are prohibited without explicit written consent.

Name

APONTIS PHARMA

Legal name

APONTIS PHARMA Deutschland GmbH & Co. KG

Website

https://apontis-pharma.de

Company type

Public

Founded year

1946

Operating status

Operating

Headcount range

101–250 employees

Short description

APONTIS PHARMA is a German specialty pharmaceutical company that develops, in-licenses, and markets Single Pill fixed-dose cardiovascular combinations via a field sales force reaching ~23,500 office-based physicians in Germany, operating within the Zentiva Group.

Ownership category

akta.pro rank

Product category

Cardiovascular Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Specialty Care Pharmaceuticals (HLAIAAAB), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Cardiovascular pharmaceuticals
• Single pill combinations
• Fixed-dose combinations
• Hypertension treatment
• Pharmaceutical wholesale

Headquarters

HQ city

Manheim

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Supply Chain, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: APONTIS PHARMA generates revenue through the sale of proprietary and licensed Single Pill products (fixed-dose combinations) and other pharmaceutical medications to the German healthcare market. Products are distributed via wholesale chains to pharmacies and directly to hospital pharmacies and clinics. Revenue is derived from product pricing to institutional buyers (wholesalers, pharmacies, clinics) in Germany.
2. Co-promotion & Fee-for-Call: APONTIS PHARMA earns revenue through co-promotion arrangements and fee-for-call services with other pharmaceutical companies. Under co-promotion, the company promotes partner products alongside its own portfolio using its established field sales force and access to ~23,500 German physicians. Fee-for-call arrangements involve providing pharmaceutical consultant services to partners for specific products or campaigns.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

APONTIS PHARMA develops, in-licenses, and markets Single Pills — fixed-dose combinations of two to three off-patent active ingredients — primarily for cardiovascular diseases (hypertension, dyslipidemia, secondary prophylaxis). The portfolio includes eleven launched Single Pills marketed exclusively in Germany, supported by a dedicated field sales force of pharmaceutical consultants with access to approximately 23,500 office-based physicians. The company also engages in co-promotion, fee-for-call, and licensing arrangements with partner pharmaceutical companies.

Product overview

APONTIS PHARMA is a pharmaceutical company known as 'The Single Pill Company', specializing in the development and marketing of Single Pills - combination products that merge two to three off-patent active ingredients in a single dosage form. The core portfolio consists of Single Pills for cardiovascular diseases (hypertension, dyslipidemia, cardiovascular secondary prophylaxis) and respiratory products. Single Pills include combinations such as Tonotec® (Ramipril/Amlodipine), Caramlo® (Candesartan/Amlodipine), AmloAtor® (Amlodipine/Atorvastatin), Iltria® (Triple: Aspirin/Atorvastatin/Ramipril), and numerous other cardiovascular combinations. The company also markets respiratory products (Atectura® Breezhaler®, Enerzair® Breezhaler®), Colxi® (Colchicine), and general healthcare products. As of 2026, the company aims to expand from 11 to at least 20 marketed Single Pills, targeting approximately 9 million potential patients.

Differentiator

Problem solved

Functional benefit

Products and services

• Tonotec® Single Pill combining Ramipril and Amlodipine for cardiovascular treatment - first Single Pill launched in 2013.
• Caramlo® Single Pill combining Candesartancilexetil and Amlodipine for hypertension.
• Biramlo® Single Pill combining Bisoprololfumarat and Amlodipine for cardiovascular treatment.
• Atorimib® APONTIS® Single Pill combining Ezetimib and Atorvastatin for lipid management.
• AmloAtor® APONTIS® Single Pill combining Amlodipine and Atorvastatin for treatment of hypertension and dyslipidemia.
• Caramlo® Ator APONTIS® Triple combination Single Pill with Candesartancilexetil, Amlodipine, and Atorvastatin for comprehensive cardiovascular care.
• ValsaInda® APONTIS® Single Pill combining Valsartan and Indapamid for hypertension.
• CandeInda® APONTIS® Single Pill combining Candesartancilexetil and Indapamid for hypertension.
• Atectura® Breezhaler® Indacaterol/Mometasonfuroat inhaler for asthma treatment.
• Enerzair® Breezhaler® Indacaterol/Glycopyrronium/Mometasonfuroat inhaler for asthma treatment.
• Colxi® Colchicine product for anti-inflammatory treatment.
• Codicaps® mono Codein Monohydrat product.
• magno sanol® Magnesiumoxid supplement.
• magno sanol® uno Magnesium supplement product.
• Obstinol® M Viscous Paraffin product.

Quantifiable outcome

• Patient adherence increases from 20-50% (conventional) to 70-80% (Single Pill)
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered flagship and core.

• AmloAtor Product Partner (name not disclosed in source)flagshipStrategic or Co-development Partner · 1 January 2022AmloAtor (Amlodipin/Atorvastatin) was launched in 2022 as a Single Pill combination product for the treatment of hypertension and dyslipidemia. APONTIS PHARMA co-promotes this product on the German market with a partner company. AmloAtor represents one of the company's newer flagship Single Pill products addressing a common comorbidity in cardiovascular patients.
• Tonotec Product Partner (name not disclosed in source)coreStrategic or Co-development Partner · 1 January 2013Tonotec (Ramipril/Amlodipin) was launched in 2013 as a Single Pill combination product. APONTIS PHARMA specializes in the development and in-licensing of fixed-dose combinations of off-patent active ingredients, and co-promotes the Tonotec brand on the German market with a partner company. The partnership has been sustained through the company's transitions from Schwarz Pharma to UCB Innere Medizin and then to APONTIS PHARMA.
• Zentiva Group (Zentiva Group, a.s.)flagshipStrategic or Co-development PartnerAPONTIS PHARMA operates as part of the Zentiva Group, an international pharmaceutical company headquartered in Prague, Czech Republic. APONTIS PHARMA and Zentiva Group (together with further affiliated companies) act as joint controllers under GDPR (Art. 26 DSGVO) for data processing purposes. Zentiva also provides the Speak-Up whistleblowing platform for APONTIS's corporate governance framework. The Zentiva partnership provides strategic oversight, shared corporate services, and access to the broader Zentiva network.

Scale indicators9 records

Recent moves10 records

Expansion highlights5 records

Emerging players

• Aristo Pharma: Aristo Pharma is a German specialty generics company with cardiovascular and chronic disease products. Comparable as a Germany-focused pharma with cardiovascular offerings and a similar mid-market positioning.
• Hexal (Sandoz): Hexal is a leading German generics manufacturer with cardiovascular portfolio. Comparable as a Germany-based company with cardiovascular offerings targeting the same primary care physician channel, though focused on generics rather than branded FDCs.

Direct peers

• Stada Arzneimittel: Stada is a German specialty pharma with cardiovascular and chronic disease products, including FDC offerings. Comparable as a mid-size European specialty pharma with German market focus and field sales force model.
• Berlin-Chemie (Menarini Group): Berlin-Chemie is a major German pharmaceutical company with strong cardiovascular portfolio and primary care physician relationships. Comparable as a Germany-focused cardiovascular pharma with established field sales infrastructure.
• Servier Deutschland: Servier markets cardiovascular FDC products (e.g., Coversyl combinations, Viacoram) in Germany. Comparable as a cardiovascular-focused pharma with fixed-dose combination strategy targeting the same physician segments.
• Daiichi Sankyo Deutschland: Daiichi Sankyo markets Sevikar (olmesartan/amlodipine) and other cardiovascular FDC products in Germany. Directly comparable as a cardiovascular fixed-dose combination competitor targeting the same German primary care physician base.

Broad incumbents

• Zentiva Group: Parent company of APONTIS PHARMA. Zentiva is a major European generics and specialty pharma company with broad cardiovascular and chronic disease portfolios. Comparable as the parent organization with overlapping cardiovascular FDC focus and shared distribution infrastructure.
• Bayer Vital (Bayer Pharma): Bayer is a major German pharmaceutical company with a significant cardiovascular portfolio and established physician relationships. Comparable as a broad incumbent in the same cardiovascular therapeutic area with overlapping primary care reach.
• Novartis Pharma Germany: Novartis markets Exforge (amlodipine/valsartan) and other cardiovascular FDC products in Germany. Comparable as a major incumbent with overlapping cardiovascular FDC portfolio and established German primary care presence.
• AstraZeneca Germany: AstraZeneca markets Caduet (amlodipine/atorvastatin) and other cardiovascular products in Germany. Comparable as a major incumbent with direct overlap in the amlodipine/atorvastatin FDC space that APONTIS addresses with AmloAtor®.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/apontis-pharma

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about APONTIS PHARMA